Z-Drug Use in the First Trimester of Pregnancy and Risk of Congenital Malformations
These findings suggest that Z-drug exposure in the first trimester of pregnancy is not associated with a meaningful elevation in the risk of congenital malformations overall, nor was there a consistent signal observed for organ-specific or uncommon, individual malformations examined.
Authors
- Kathryn J. Gray (ORCID: https://orcid.org/0000-0002-3541-3724)
- Sonia Hernández–Dı́az (ORCID: https://orcid.org/0000-0003-1458-7642)
- Loreen Straub (ORCID: https://orcid.org/0000-0003-2623-2726)
- Krista F. Huybrechts (ORCID: https://orcid.org/0000-0001-5805-8430)
- Brian T. Bateman (ORCID: https://orcid.org/0000-0001-5950-8683)
- Yanmin Zhu
- G. Brill
- Kelly Fung (ORCID: https://orcid.org/0009-0004-6282-1362)
- Lee S. Cohen
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- University of Washington (US)
- Massachusetts General Hospital (US)
- Stanford University (US)
Publication Details
- Journal
- JAMA Psychiatry
- Published
- 2025-12-23
- DOI
- https://doi.org/10.1001/jamapsychiatry.2025.3874
- Primary Topic
- Maternal Mental Health During Pregnancy and Postpartum
- Type
- article
- Field-Weighted Citation Impact
- 0.00